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A
 
BSTRACT
 
It is believed that G-protein-coupled receptors are
the most promising target proteins for drug research.
The 
 
β
 
2
 
-adrenergic receptor has been analyzed exten-
sively in terms of its structure, regulation and signaling
as a prototype G-protein-coupled receptor. Recent
development of a recombinant 
 
β
 
2
 
-adrenergic receptor
reveals that the receptor exists in different confor-
mations in addition to the resting and active forms.
Furthermore, different conformations that are impor-
tant for coupling with G-proteins are induced in a
ligand-specific manner. After the receptor binds an
agonist, the receptor is phosphorylated by G-protein-
coupled receptor kinase or second messenger-
dependent kinase. 
 
β
 
-Arrestin is a cytosolic protein that
binds to receptors phosphorylated by G-protein-
coupled receptor kinase, but not those phosphorylated
by second messenger-dependent kinase, and plays
important roles in agonist-induced desensitization.
However, 
 
β
 
-arrestin has recently been recognized as
a scaffold protein that helps to achieve efficient
transmission of internalization and signaling. Receptor
agonists can be divided into two groups: full and
partial agonists. Partial agonists have an advantage
over full agonists because desensitization is less likely
to be induced following stimulation with a partial
agonist. However, the effects of partial agonists on
 
β
 
-arrestin-mediated signaling and internalization have
not been fully examined so far. Information regarding
the binding sites of partial agonists is still not sufficient
to explain why they cannot fully activate the receptor.
In the present study, recent progress regarding the
structure, regulation and signaling of 
 
β
 
2
 
 adrenergic
receptors and about differences between full and
partial agonists will be summarized.
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I
 
NTRODUCTION
 
G-protein-coupled receptors (GPCR) are well known as
drug targets. In fact, the targets of approximately 50% of
drugs that are available commercially on the market are
GPCR.
 
1
 
 The 
 
β
 
-adrenergic receptor is considered as a
prototype GPCR and has been studied extensively.
 
β
 
-Adrenergic receptors are classified into three sub-
types: 
 
β
 
1
 
, 
 
β
 
2
 
 and 
 
β
 
3
 
. The 
 
β
 
1
 
-adrenergic receptor subtype
is mainly involved in increasing heart rate and causing
contraction of the heart, whereas stimulation of the
 
β
 
2
 
-adrenergic receptor subtype relaxes smooth muscle.
The 
 
β
 
3
 
-adrenergic receptor subtype is speculated to be
a promising target for anti-obesity drugs. Drugs are
defined by three properties: affinity, efficacy and dura-
tion of action. Each drug has its own intrinsic properties.
Of the three drug properties, subtype selectivity is linked
directly to affinity and is important for drug treatment,
because serious side-effects can be avoided using
drugs with higher receptor affinity. The binding site of
 
β
 
2
 
-adrenergic receptors has been analyzed extensively
among the GPCR and a model of the agonist–receptor
complex has been proposed. In the present review, the
current understanding of various aspects of 
 
β
 
2
 
-adrenergic
receptors, such as agonist-induced conformational
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changes of the receptor, regulation, signaling and the
relationship between polymorphism and drug response,
will be summarized. In addition, differences between
partial and full agonists will be discussed.
 
A
 
GONIST
 
 
 
BINDING
 
 
 
SITE
 
 
 
OF
 
 
 
β
 
2
 
-
 
ADRENERGIC
 
 
 
RECEPTORS
 
The GPCR exist on the cell surface and bind agonists
to elicit cellular responses. Recent progress in receptor
research reveals that a small number of of receptors exist
in the active state even in the absence of an agonist and
that receptors are in equilibrium between the resting
and active states (Fig. 1).
 
2
 
 Drugs acting on receptors are
classified into two groups: agonists and antagonists.
Antagonists are further divided into neutral antagonists
and inverse agonists. Neutral antagonists bind to recep-
tors in the resting or active state, but do not change the
equilibrium between the two states. In contrast with
neutral antagonists, inverse agonists shift the equilibrium
towards the inactive state. Agonists are divided into
partial and full agonists. Full agonists are defined as
agonists that maximally activates the receptor, whereas
partial agonists are defined as agonists that cannot fully
activate the receptor even though all receptors are
occupied by the agonist. Agonists should bind to critical
amino acids for activation of G-proteins. It has been
demonstrated that aspartic acid at position 113 (Asp
 
113
 
)
of the human 
 
β
 
2
 
-adrenergic receptor binds to the amino
group of the full agonist isoproterenol and that Ser
 
204
 
and Ser
 
207
 
 interact with the catechol hydroxyl group at
the 
 
meta
 
 or 
 
para
 
 positions of isoproterenol, respectively
(Fig. 2).
 
3
 
 Based on these results, it is reasonable to
assume that a full agonist is converted to a partial
agonist when the interaction between the receptor and
full agonist is disrupted by steric hindrance of the
receptor or chemical modification of the agonist. In
addition to Ser
 
204
 
 and Ser
 
207
 
, we have demonstrated
previously that another Ser (Ser
 
203
 
) next to Ser
 
204
 
 is also
involved in the interaction with the hydroxyl group of
catechol at the 
 
para
 
 position.
 
4
 
 Our finding was later
confirmed by Liapakis 
 
et al
 
.
 
5
 
 Asparagine at position 293
(Asn
 
293
 
) has been proposed to interact with the hydroxyl
group at the 
 
β
 
 position that determines the stereospecific
interaction of an agonist with the receptor.
 
6
 
 However,
isoproterenol does not show subtype selectivity for
 
β
 
1
 
- and 
 
β
 
2
 
-adrenergic receptors. Thus, we determined
the binding site on the 
 
β
 
2
 
-adrenergic receptor conferring
subtype-selective, high-affinity binding.
 
7–9
 
 We also deter-
mined the structural requirements for an agonist to be
subtype selective for the 
 
β
 
2
 
-adrenergic receptor.
 
B
 
INDING
 
 
 
SITE
 
 
 
FOR
 
 
 
β
 
2
 
-
 
ADRENERGIC
 
 
 
RECEPTOR
 
-
 
SELECTIVE
 
 
 
AGONISTS
 
There are many agonists that show 
 
β
 
2
 
-adrenergic
receptor selectivity, such as salmeterol, procaterol and
formoterol. Among the 
 
β
 
2
 
-adrenergic receptor-selective
agonists, we first used TA-2005 to determine 
 
β
 
2
 
-adrenergic
receptor subtype-selective binding sites, because deriva-
tives of TA-2005 are available for analysis.
 
7
 
 It has been
reported that TA-2005 has a long duration of action in
addition to 
 
β
 
2
 
-adrenergic receptor selectivity.
 
10
 
 TA-2005
has structural features that include saligenin and meth-
oxyphenyl groups. Among the derivatives of TA-2005,
the compound that lacks the methoxyphenyl group lost
 
β
 
2
 
-adrenergic receptor selectivity and the affinity of this
compound for 
 
β
 
2
 
-adrenergic receptors was essentially
the same as for 
 
β
 
1
 
-adrenergic receptors.
 
7
 
 This demon-
strates the importance of the methoxyphenyl group of
TA-2005 for 
 
β
 
2
 
-adrenergic receptor selectivity. Structural
analysis of subtype-selective agonists has revealed an
interesting structure that is often attached to the amino
group of the agonist,
 
7
 
 consistent with our results. Our
results also indicate that 
 
β
 
2
 
-adrenergic receptors have
 
Fig. 1
 
Equilibrium between resting and active states of a
receptor. Receptors exist in the active (R*) and resting (R) states
even in the absence of agonist stimulation. Agonist stimulation
shifts the equilibrium towards the active state (R*), which couples
with and activates G-proteins. The introduction of a mutation at
specific positions of the receptor results in a constitutively active
receptor. Inverse agonists, but not neutral antagonists, shift
the equilibrium towards the resting state. G, G*, resting and
active states of G-protein, respectively.
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region(s) or amino acid(s) that are responsible for
binding of the methoxyphenyl group of TA-2005. By
constructing various chimeric 
 
β
 
1
 
- and 
 
β
 
2
 
-adrenergic
receptors, we have identified the seventh transmembrane
domain (TM7) as the most important domain for
 
β
 
2
 
-adrenergic receptor-selective, high-affinity binding.
 
7
 
Then, the 10 amino acids in TM7 that are different to
that of the 
 
β
 
1
 
-adrenergic receptor were individually
mutated to Ala. The resulting Ala-substituted mutants
demonstrated that mutation of Tyr
 
308
 
, but not other
amino acids, decreased the affinity of the receptor for
TA-2005. These results indicate that Tyr
 
308
 
 is a major
determinant for high-affinity binding of 
 
β
 
2
 
-adrenergic
receptor-selective agonists. The model of the 
 
β
 
2
 
-adrenergic
receptor–TA-2005 complex is shown in Fig. 3. Sub-
sequent experiments from our group demonstrated that
 
Fig. 2
 
A model of the 
 
β2-adrenergic receptor–isoproterenol complex. Isoproterenol is a full agonist and is used for analysis as a
typical agonist. The amino group of isoproterenol interacts with Asp113 in the third transmembrane domain (TM3), which plays an
essential role in binding of the β-adrenergic receptor agonist. (a) A schematic model of the isoproterenol–β2-adrenergic receptor
complex is shown to demonstrate the amino acids that interact with isoproterenol. (b) Three-dimensional model of the isoproter-
enol–β2-adrenergic receptor complex (reproduced with permission from Furse and Lybrand23).
Fig. 3 A model of the β2-adrenergic receptor–TA-2005 complex. TA-2005 is a β2-adrenergic receptor-selective agonist that binds
β2-adrenergic receptors with high affinity. The methoxyphenyl group of TA-2005 interacts with Tyr308 in the seventh transmembrane
domain (TM7), which plays a most important role in β2-adrenergic receptor selectivity. (a) A schematic model of the β2-adrenergic
receptor–TA-2005 complex is shown to demonstrate the amino acids that interact with TA-2005. (b) Three-dimensional model of
the TA-2005–β2-adrenergic receptor complex complex (reproduced with permission from Furse and Lybrand23).
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Tyr308 is important for β2-adrenergic receptor-selective,
high-affinity binding not only of TA-2005, but also of
other β2-adrenergic receptor-selective agonists such as
salmeterol, procaterol and formoterol.8,9
BINDING TO A CONSTITUTIVELY ACTIVE 
RECEPTOR
When a mutation is introduced at a specific location in
the β2-adrenergic receptor, the receptor assumes to trans-
form into an active conformation even in the absence
an agonist.11 This is referred to as a constitutively active
receptor. When the amino acids Leu266, Lys267, His269
and Leu272 at the end of the intracellular third loop were
mutated to Ser, Arg, Lys and Ala locating, the resultant
β2-adrenergic receptor became a constitutively active
receptor, because it could stimulate adenylyl cyclase
without the presence of an agonist and showed a high-
affinity state for agonists.11 Although neutral antago-
nists did not decrease basal adenylyl cylase activity of
the mutant receptor, inverse agonists decreased its
activity. Therefore, it is concluded that the mutation
transforms the receptor into an active form.
It is believed that the β2-adrenoceptor has at least
two different conformations: resting and active. However,
it is not certain whether the mutation-induced active
conformation of the β2-adrenergic receptor is the same
conformation as that induced by agonist binding. When
agonist-binding characteristics were examined in consti-
tutively active β2-adrenergic receptors,11 all agonists had
increased affinity for the constitutively active receptor. It is
interesting that the increased affinity of an agonist for the
receptor depends on its efficacy. Because the receptor in
an active conformation has a higher affinity for agonists
than receptors in the resting state, mutation really creates
an active receptor. The degree of the increase in the
affinity of partial agonists is lower than that of full ago-
nists. To examine conformational changes occurring in
the binding sites of β2-adrenergic receptor-selective ago-
nists upon activation, substitution of Ser204 or Ser207 with
Ala was introduced into the constitutively active mutant
β2-adrenergic receptor.12 When the binding characteris-
tics of the Ala-substituted constitutively active mutant
receptor were compared with those of the constitutively
active mutant, the following binding characteristics were
found. In the resting state, salmeterol, salbutamol and
TA-2005 interact more strongly with Ser204 of the
β2-adrenergic receptor than Ser207. In contrast with the
resting state of the receptor, these three β2-adrenergic
receptor-selective agonists interact equally with Ser204
and Ser207 in the active state. However, isoproterenol
interacts equally with Ser204 and Ser207 in both the resting
and active states. Thus, salmeterol, salbutamol and
TA-2005, but not isoproterenol, interact equally with
Ser204 and Ser207 of the receptor in the active conforma-
tion. These results indicate that the interaction between
the saligenin group of the agonist and the two Ser resi-
dues is different for β2-adrenergic receptors in the resting
state compared with the active state.
INVOLVEMENT OF DIFFERENT AMINO ACIDS IN 
THE BINDING OF AGONISTS AND ANTAGONISTS
The binding site for β2-adrenergic receptor subtype-
selective antagonists has been determined by construct-
ing chimeric β1- and β2-adrenergic receptors. Marullo
et al. demonstrated that high-affinity binding for β2-
adrenergic receptor-selective antagonists was not deter-
mined by a single transmembrane domain, but that it is
determined by more than two transmembrane domains
in a concerted manner.13 However, it would be difficult
to confirm the involvement of a single transmembrane
domain in the high-affinity binding of β2-adrenergic
receptor subtype-selective antagonists, because these
compounds interacted with more than two trans-
membrane domains at the same time. Although it is not
definitive, the conclusion of Marullo et al.13 is plausible
because the role of antagonists is to prevent the receptor
from becoming activated by binding to any domain of
the receptor. In contrast with the antagonists, β2-adren-
ergic receptor subtype-selective agonists must activate
the receptor by binding to a specific set of amino acids
that are important for activation. There are several
amino acids that are necessary for inducing the active
conformation of the receptor following agonist binding.
Full agonists interact with several critical amino acids
to maximally activate G-proteins. When a full agonist
loses the interaction with some of the G-proteins, it
becomes a partial agonist. Strader et al. reported that a
Ser204 or Ser207 to Ala mutation resulted in receptors for
which isoproterenol no longer behaves as a full ago-
nist.14 Isoproterenol becomes a partial agonist in these
mutants. Strader et al.14 have demonstrated that sub-
stitution of the catechol hydroxyl group with a hydrogen
decreases the affinity of agonists for wild-type β2-adrenergic
receptors and, thus, reduces their efficacy because the
interaction important for full activation is lost following
the Ala substitution.
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AGONIST-SPECIFIC CHANGES IN RECEPTOR 
CONFORMATION
It has been reported that various β-adrenergic receptor
agonists differentially couple with Gs, Gi and Gq.15 To
explain this phenomenon, it has been postulated that
β2-adrenergic receptors take on different conformations
that are important for coupling with G-proteins.15–17
Ghanouni et al. demonstrated that antagonist-, full
agonist- and partial agonist-bound states are clearly
different from each other.18 Ghanouni et al. covalently
attached a fluorophore to the G-protein-coupling domain
of purified β2-adrenergic receptors and determined the
fluorescence lifetime of the fluorophore. When a full
agonist bound to the receptor, the G-protein-coupling
domain showed two different conformations. Further-
more, the conformation induced by partial agonists is
different from that induced by full agonists. This group
also monitored agonist-induced conformational changes
over time and demonstrated that agonists stabilize a
succession of conformational states with distinct cellular
functions.19 However, the exact relationship between the
nature of the agonist and the conformation linked to
G-protein activation remains to be determined.
Basal cAMP production of constitutively active mutants
increases as receptor expression levels increase. When
various amino acids were introduced at the end of
the intracellular third loop of α1-adrenergic receptors,
the resulting mutants showed various degrees of constitu-
tive activity.20 This leads to speculation that receptors take
on many conformations that determine the degree of
interaction with G-proteins (Fig. 4). The nature of the
agonist determines the degree of coupling with G-proteins
and it may determine the species of G-protein bound.
Many β-adrenergic receptor agonists stimulate not
only Gs, but also Gq and Gi to various degrees.15,17
G-Proteins are divided into four families: Gs, Gi, Gq
and G12. So far, it has not been determined whether
β2-adrenergic receptors couple with the G12 family of
G-proteins (G12 and G13) in an agonist-specific manner.
It would be interesting to determine the coupling of
β2-adrenergic receptors with G12 and G13, because the
G12 family of G-proteins mainly regulates the small
G-protein Rho, which plays an important role in the con-
traction of smooth muscle, cytoskeletal rearrangement,
cell movement and cell growth.21 Smooth muscle is
relaxed by stimulation of β2-adrenergic receptors.22
Agonist stimulation of β2-adrenergic receptors may acti-
vate the Rho signaling pathway as well as the Gs–cAMP
pathway. When β2-adrenergic receptor stimulation
relaxes smooth muscle, it may activate a contraction
pathway through the G12–Rho pathway to avoid a maxi-
mally relaxed state.
Relationship between the β2-adrenergic 
receptor-selective biding site and the exosite 
of salmeterol
Our group has reported previously that Tyr308 in TM7
plays an important role in the high-affinity binding of β2-
adrenergic receptor-selective agonists such as TA-2005,
salmeterol, procaterol and formoterol.7–9 When Tyr308
was mutated to Ala, the resulting mutant had decreased
affinity for all β2-adrenergic receptor-selective agonists.
Because procaterol does not have a long substituted
group at the amino group, contact with Tyr308 in TM7
would seem difficult. However, the affinity for procaterol
was decreased in Ala-substituted mutants of Tyr308, like
for other β2-adrenergic receptor-selective agonists. The
three-dimensional model of the β2-adrenergic recep-
tor–ligand complex suggested that Tyr308 locates above
the substitute of the amino group and restricts the
movement of the substituted group to the extracellular
space from the upper side like a lid.23 TA-2005 has a
high affinity for β2-adrenergic receptors and a relatively
long duration of action compared with salbutamol.
However, the duration of action of TA-2005 is shorter
than that of salmeterol. Salmeterol has a unique struc-
ture that is a long hydrophobic chain attached at the
Fig. 4 Agonist-induced specific conformational changes of
receptors. β2-Adrenergic receptors can exist in different con-
formations that are induced in an agonist-specific manner.
Receptors in each conformation may couple with a specific set
of G-proteins, which leads to different cellular responses.
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amino group.24 The long hydrophobic chain is important
not only for β2-adrenergic receptor selectivity, but also
for the duration of action. The amino acid region that is
necessary for the duration of action is different from that
necessary for high-affinity binding. It is postulated that
the long chain of salmeterol binds to a specific region of
the receptor referred as the exosite, which allows it to
persistently bind to the receptor.24 Green et al. reported
that lower half region of TM4 of the β2-adrenergic
receptor is the site of the exosite.25 They constructed
various chimeric β2- and β1-adrenergic receptors and
determined the region that is essential for the long
duration of action of salmeterol. Because β1-adrenergic
receptors do not bind salmeterol with high affinity and
persistency, one of the chimeric receptors should reveal
the critical region of the exosite. The chimeric approach
also eliminates the possibility that the major exosite is a
membrane lipid bilayer close to the receptor, because
all chimeric receptors were expressed on the same
cellular background. Green et al.25 demonstrated that
the chimeric receptor with TM4 of the β1-adrenergic
receptor loses the long duration of action. Thus, they
concluded that TM4 is a major candidate for the exosite.
In contrast with the importance of TM7 for β2-adrenergic
receptor selectivity, TM4 is important for the duration of
action, but does not play any role in β2-adrenergic
receptor-selective, high-affinity binding. In fact, the β2/β1
chimeric receptor with the lower half region of TM4 of
the β1-adrenergic receptor still retained its β2-adrenergic
receptor selectivity for salmeterol comapred with wild-
type β2-adrenergic receptor.25 Rong et al. reported another
candidate region for the exosite using a novel photo-
affinity probe for salmeterol.26 Its photoactivatable azide
locates at the extreme end of the N-aryloxyalkyl chain of
salmeterol, which confers the long duration of action
of salmeterol. This probe labeled TM6 and TM7 of the
β2-adrenergic receptor. Therefore, Tong et al. concluded
that the exosite was located at TM6 and TM7 in addition
to the lipid bilayer.26 We have previously identified TM7
as the region that is essential for β2-adrenergic receptor-
selective, high-affinity binding.7–9 Therefore, β2-adrenergic
receptor selectivity and duration of action is governed by
different regions of the receptor.
RESPONSES TO PARTIAL AGONISTS
Partial agonists cannot activate the receptor fully. How-
ever, partial agonists can induce cellular or tissue
responses in similar extent to those induced by a full
agonist. The receptor-mediated signaling is amplified at
each step, as upstream signaling molecules produce an
excess amount of messenger over the number of down-
stream signaling molecules. Thus, the final response is
maximally induced by a small portion of upstream
signaling molecules. Therefore, the dose–response curve
of the final response will be shifted to the left compared
with that obtained following binding of an agonist to the
receptor. This is the reason that weak activation of
receptors by partial agonists can still induce maximal
responses in cells or tissues.
Signaling by β2-adrenergic receptor stimulation is
almost exclusively through adenylyl cyclase and protein
kinase A (PKA) activation. However, it has been reported
that stimulation of β2-adrenergic receptors induces several
responses via activated Gs but not adenylyl cyclase and PKA
activation.27 For instance, calcium channels, c-Src tyrosine
kinase and RGS-PX1 (one of the sorting nexins) have been
reported to interact with and be activated by Gs.27 The
effects of partial agonists on these effectors have not been
determined in detail yet. It is interesting to examine the
effects of partial agonists on effectors other than adenylyl
cyclases, because they may elicit physiological responses
via a cAMP (adenylyl cyclase)-independent pathway.
DESENSITIZATION AND PARTIAL AGONISTS
What is a clinical benefit of partial agonists? Partial
agonists are believed to induce less desensitization than
full agonists.28 Desensitization is defined as a reduced
response upon second stimulation.29 When the second
stimulant is the same as the first stimulant, the phenom-
enon is referred as homologous desensitization. When
the second stimulant is different from the first stimulant
and still shows a reduced response, it is referred as
heterologous desensitization. Desensitization consists of
three processes: uncoupling, internalization and down-
regulation. Uncoupling occurs in seconds. Internaliza-
tion occurs in minutes and downregulation occurs in
hours to days (Fig. 5). The most important factor for
desensitization is downregulation at the whole-body
level becase an agonist is administered for long periods
of time to treat disease. The number of receptors is kept
low (typically fmol/mg protein) in native cells and
agonist-induced responses are positively correlated with
the number of receptors. When receptor expression
levels are decreased by agonist stimulation, there is a
direct link with the decreased response. Because
agonists are frequently used for the treatment of disease,
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it is necessary to elucidate the mechanism of down-
regulation. Furthermore, elucidation of the mechanism
of agonist-induced downregulation may lead to the
discovery of a novel therapeutic target for drug research.
A detailed mechanism for downregulation has not been
established so far. However, it is believed that a part of
the downregulation process is possibly mediated by a
second messenger-dependent pathway. Because agonist
efficacy correlates with the production of second
messengers, such as cAMP and Ca2+, it is beneficial to
use partial agonists to avoid downregulation.
There are several mechanisms through which recep-
tors can be downregulated: (i) increased degradation of
receptor protein; (ii) decreased transcription of receptor
mRNA; (iii) decreased synthesis of receptor protein; and
(iv) decreased stability of receptor mRNA. Second mes-
sengers are involved, at least, in the decreased stability of
mRNA.30 The degree of contribution of the other mecha-
nisms to downregulation is not known. Partial agonists do
not increase second messengers to the same extent as full
agonists. Thus, treatment with partial agonists induces
less downregulation than that induced following treat-
ment with a full agonist. Accelerated degradation of
receptor protein is partially mediated by internalization
and then targeting to the lysosome.29,31 Although the
mechanism of targeting to the lysosome is unknown, the
internalization process that partially links to lysosome
targeting is dependent on the strength of agonist stimula-
tion. Therefore, partial agonists have an advantage over
full agonists because they induce a lesser degree of
downregulation through the lysosome.
INTERNALIZATION, LYSOSOME TARGETING AND 
DESENSITIZATION
Internalization of the GPCR has been studied extensively
for β2-adrenergic receptors and a basic mechanism of
internalization is emerging.31 Agonist stimulation leads
to phosphorylation of the receptor by G-protein-coupled
receptor kinase (GRK). The GRK only phosphorylates
receptors in an active conformation. The degree of
GRK-mediated phosphorylation following agonist stimu-
lation is correlated with the efficacy of an agonist.32
Receptors phosphorylated by GRK, but not second
messenger-dependent protein kinases, such as PKA, are
targeted by β-arrestin. β-Arrestin is a cytosolic protein
that translocates to the membrane following agonist
stimulation. Coupling with the G-protein is then inhib-
ited by receptor-bound β-asrrestin. The GRK also have
a regulator of G-protein signaling (RGS) domain that
binds to G-proteins and accelerate GTPase activity.33
Therefore, GRK participates in uncoupling by two mech-
anisms: (i) the inhibition of coupling by phosphorylation;
and (ii) the increased turn-off reaction by the RGS
domain. β-Arrestin binds clathrin and adaptin, the
interaction of which is essential for agonist-stimulated
internalization through clathrin-coated pits.29,31 After
β2-adrenergic receptors are internalized, a part of the
receptor is targeted to the lysosome.29,31 Although it is
not known what signal targets the receptor to the
lysosome, the carboxyl terminal PDZ domain of the
β2-adrenergic receptor has been proposed to be main
determinant of lysosome targeting.34 The phosphory-
lation of amino acids in the PDZ domain switches the
receptor from a recycling process to lysosome targeting.
This phosphorylation of the PDZ domain has been
reported to be mediated by GRK5.34 The GRK5-mediated
phosphorylation results in the release of Na+/H+
exchanger regulatory factor (NHERF), which binds this
carboxyl terminal PDZ domain. Then, the phosphory-
lated receptor is targeted to the lysosome.
β-Arrestin works as an adaptor protein linking β2-
adrenergic receptors to internalization. However, a
β-arrestin-independent internalization pathway also exists,
which is believed to depend on the type of receptor.31
Fig. 5 Schema of the internalization, recycling and degrada-
tion of receptors. Agonist stimulation leads to G-protein-
coupled receptor kinase-mediated phosphorylation and the
phosphorylated receptor recruits β-arrestin to the membrane.
The receptor–β-arrestin complex is trafficked to the endosome
and recycled back after dephosphorylation. Some of the
internalized receptors are targeted to the lysosome for degrada-
tion. The processes of internalization, translocation to the endo-
some and recycling occurs rapidly or slowly, depending on the
type of receptor.
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Ubiquitination is a signal of protein degradation.
Shenoy et al. reported that β2-adrenergic receptors and
β-arrestin are ubiquitinated when the receptors were
stimulated by the agonist isoproterenol.35 Two hybrid
assays revealed that β-arrestin interacts with one of the
ubiquitin ligases (Mdm2) and that this interaction is
essential for ubiquitination of β-arrestin. The Mdm2-
mediated ubiquitination of β-arrestin is required for
receptor-mediated internalization. However, ubiquitina-
tion of β2-adrenergic receptors is mediated by an
unidentified ubiquitin ligase and the role of receptor
ubiquitination has not been determined.
It is generally believed that receptor internalization
does not contribute to desensitization.29 Instead, internal-
ization is proposed to be a process of resensitization
through dephosphorylation by internalized vesicle-
associated phosphatase.31,36 However, the mechanism of
desensitization has been examined in artificially over-
expressing cells in almost all cases. The level of expres-
sion in native cells or tissues is relatively low compared
with overexpressing cells. Because the receptor-mediated
response positively relates with the number of receptors
expressed on the cell surface, internalization may contrib-
ute to the uncoupling of the receptor from G-proteins
under the physiological circumstances.
Receptor phosphorylation is not enough for tight
binding of β-arrestin to the phosphorylated receptor.31
The tight binding of β-arrestin to the phosphorylated
receptor requires the presence of an agonist. Therefore,
the agonist-bound and phosphorylated receptor binds
β-arrestin tightly and, consequently, is uncoupled from
G-proteins. Partial agonists cause less desensitization
than full agonists, because partial agonist-induced
phosphorylation by GRK and the subsequent binding of
β-arrestin is weaker than for full agonists.28
The structural determinant of rapid recycling or lyso-
some trafficking exists in the receptor sequence itself,
because two different receptors expressed in the same
cell show different behaviors of recycling and degrada-
tion. However, it is more complex than thought, because
opiate receptor trafficking to the lysosome is dependent
on the type of agonist.37–39 Trafficking of β2-adrenergic
receptors to the lysosome may also be dependent on the
agonist and partial and full agonists can differentially
regulate lysosome trafficking.
CENTRAL ROLE OF β-ARRESTIN IN RECEPTOR 
REGULATION AND SIGNALING
β-Arrestin is a cytosolic protein that binds to the
phosphorylated and activated form of the receptor.29,31
The binding of β-arrestin uncouples the receptor from
G-proteins. However, the binding of β-arrestin to the
phosphorylated receptor also produces new signaling.
It mediates mitogen-activated protein kinase activation,
such as extracellular signal-regulated kinase (ERK) 1/2
and c-Jun NH2-terminal kinase (JNK) 3 by interacting
Table 1 β-Arrestin-interacting proteins
Proteins interacting with β-Arrestin signaling
Extracellular signal-regulated kinase
Raf1
Apoptosis-stimulating kinase 1
c-Jun N-terminal kinase 3
c-Src (SH1, SH3 domains)
Proteins interacting with β-Arrestin feedback regulation
Phosphodiesterase 4
Proteins interacting with β-Arrestin internalization
Mdm2 (ubiquitin ligase 3)
Clathrin
Adaptor protein 2
β-Arrestin interacts with various proteins that are involved in internal-
ization and signaling. These proteins are divided into three groups:
signaling, feedback regulation and internalization. (See text for details.)
Fig. 6 Polymorphism of human β2-adrenergic receptors. It
has been reported that amino acids Arg, Gln, Met or Thr at
position 16, 27, 34 or 164 are changed to Gly, Glu, Val or Ile,
respectively.40 In addition to these polymorphisms, there is
a polymorphism at the 5′ leader cistron (–47 nucleotide)
encoding the 19 amino acid peptide referred as the β2-adrenergic
receptor upstream peptide (BUP), which controls translation of
the β2-adrenergic receptor. The amino acid Arg19 in the BUP is
changed to Cys by this polymorphism. Two polymorphisms are
presented in the figure. The change of Arg16 in the coding
region to Gly is proposed to be linked with the albuterol
response.42,43 (Refer to the text for details.)
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with various regulatory proteins, such as JNK, apoptosis-
stimulating kinase and Src.30 Thus, β-arrestin has been
proposed to be a scaffold protein that assembles signal-
ing molecules to efficiently transduce the signal down-
stream (Table 1). Unfortunately, the differential effects of
agonists, including full and partial agonists, have not yet
been determined.
POLYMORPHISM OF β2-ADRENERGIC RECEPTORS 
AND AGONIST ACTIONS
Polymorphism is defined as the genetic variation
observed in more than 1% of the population. It has been
reported for human β2-adrenergic receptors that Arg,
Gln, Met and Thr at positions 16, 27, 34 and 167 are
changed to Gly, Glu, Val and Ile, respectively (Fig. 6).40
Green et al. reported the relationship between poly-
morphism of Arg16 and agonist-induced regulation.41
They expressed the Gly- or Glu-substituted mutants
and compared the pharmacological and biochemical
characteristics of these mutants, such as binding and
desensitization, with those of the wild-type receptor.
Green et al.41 found that substitution of Arg at position
16 with Gly results in a receptor that shows slightly, but
significantly, enhanced downregulation following pro-
longed stimulation with isoproterenol. The clinical signif-
icance of substitution of Arg to Gly has been reported by
two groups. Martinez et al. have found that homozy-
gotes and heterozygotes for Arg16 were 5.3- and 2.3-
fold, respectively, more likely to respond to albuterol.42
Albuterol is a partial agonist and is used in the treatment
of asthma. The responses to albuterol were correlated
with genetic variation at Arg16. Israel et al. have reported
that the homozygous Arg16/Arg16 patient shows clear
tachyphylaxis, although patients within the entire popu-
lation did not show tachyphylaxis following regular
use of albuterol.43 Further investigations will help to treat
patients based on their genetic background.
CONCLUSIONS
β2-Adrenergic receptors have been analyzed in detail in
terms of their structure and functional regulation. It has
been shown that agonist binding to the receptor induces
ligand-specific conformational changes and subsequent
signaling through G-proteins. Partial agonists can be differ-
entiated from full agonists by the ability to activate G-
proteins and partial agonists produce less desensitization.
Almost all research has been performed with full agonists
and the detailed analysis of the regulation and signaling
induced by partial agonists has not been determined.
Because partial agonists are used for clinical purposes, it is
necessary to examine the signaling, regulation and binding
of β2-adrenergic receptors induced by partial agonist.
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